Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

OncoArendi to advance OATD-01 in asthma
November 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

WARSAW, Poland—OncoArendi Therapeutics Ltd. has announced the selection of OATD-01, an orally active, nonsteroidal small-molecule inhibitor of human and murine acidic mammalian chitinase, as its clinical development candidate for asthma. The company expects to submit its first IND application by mid-2017. OATD-01, presumed to be the first chitinase inhibitor to enter development according to available information, has demonstrated excellent oral pharmacokinetic characteristics in three species, as well as high bioavailability, low clearance and high volume of distribution. Its overall drug metabolism and pharmacokinetics profile is consistent with once-daily oral dosing for humans, and it has shown anti-inflammatory activity superior to Singulair. Work to support IND-enabling preclinical testing of the compound is already underway, and the first in-human studies are expected to launch in the second half of 2017.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.